The Economic Burden of COVID-19 Vaccine Hesitancy: A Systematic Literature Review

Amy Wu[1], Paige Q. Ngo[1], Colleen R. Higgins[1], Sachiko Ozawa[1]

1. Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill NC, USA

BACKGROUND

Vaccine hesitancy was named as one of the top ten threats to global health in 2019 by the World Health Organization.[1]

Although the clinical and economic benefits of vaccination are well established, **the economic impact of COVID-19 vaccine hesitancy has yet to be quantified.**

This literature review seeks to describe the economic burden associated with COVID-19 vaccine hesitancy throughout the course of the pandemic.

METHODS

PubMed, Embase, EconLit, ProQuest, & Scopus were searched from March 1, 2020, to September 8, 2023, for articles on the economic costs of COVID-19 vaccine hesitancy, following PRISMA 2020 checklist criteria.

The search strategy was developed using keywords related to **COVID-19, vaccine hesitancy, and economic costs.** Inclusion criteria for article type includes English language, conference abstracts, and full-text publications that estimated the costs of COVID-19 vaccine hesitancy through modeling, willingness to pay, or incentive studies.

RESULTS

Figure 1: PRISMA Diagram

RESULTS

The review included a total of 47 articles, with 7 **economic modeling studies** forecasting vaccine hesitancy costs, 21 studies on willingness-to-pay (**WTP**) and willingness-to-accept (**WTA**), and 19 studies on **lottery and guaranteed incentive** schemes and their impact on vaccine uptake.

Economic Modeling and Cost Studies

Table 1: Summary of Economic Modeling and Cost Analyses (n=7)

Author	Country	Study Design	Results
Amin et al, 2021	United States	Retrospective cohort analysis	From June through November 2021, preventable COVID-19 hospitalizations among unvaccinated adults cost over $13B
Bagshaw et al, 2022	Canada	Retrospective cohort analysis	Unvaccinated persons resulted in $61.3M of avoidable ICU costs between September 2021– January 2022
Bartsch et al, 2021	United States	Computational model	For every 1% increase in vaccination coverage (between 40%-50% total coverage) $602.8M would be saved in direct medical costs and $1.3B in productivity losses
Bruns et al, 2021	United States	Regulatory impact analysis	Total voluntary COVID-19 non-vaccination has caused at least $1B of harm each day in the United States since vaccines became widely available – in June-July 2021
Council of Canadian Academies, 2023	Canada	Computational model	Unvaccinated people who believed COVID-19 is a hoax or exaggerated added $300 million CAD to hospitalization and ICU costs in Canada in March-November 2021
Liu et al, 2023	Global (27 African Countries)	Cost-effective analysis	At all income levels, medium and fast vaccine roll-out scenarios are associated with lower ICERs relative to GDP per capita compared to slow
Oliu-Barton et al, 2022	Global (OECD Countries)	Time series cross-country regression analysis	Full vaccination across France, Germany, and Italy would recover 85% of the GDP lost in 2020

WTP & WTA Studies

Figure 2: Outcomes reported in WTP/WTA Studies (n=21)

- Studies reporting WTP
- Studies reporting WTA
- Studies reporting both WTP/WTA

The 21 WTP/WTA studies were conducted across multiple countries including Chile (n=2), China (n=5), Ecuador (n=1), India (n=2), Ethiopia (n=1), Indonesia (n=1), Kenya (n=1), Malaysia (n=2), Namibia (n=1), Nigeria (n=1), Vietnam (n=1), Romania (n=1), and the US (n=3). The number of respondents in each study ranged from **301 to 4,164**.

Participants' mean WTP for vaccination ranged from (n=15):

$1.60 ⟷ **$259.51**

The percentage of patients willing to accept vaccination at no cost ranged from (n=8):

40.8% ⟷ **100%**

Vaccine Hesitancy Lottery and Guaranteed Incentive Studies

Among the 19 studies reporting COVID-19 vaccine lottery and guaranteed incentives, a majority were performed in the US (n = 17) and the remaining in Germany (n = 2).

Lottery incentives ranged from:

$34K ⟷ **$5M**

Guaranteed incentives ranged from:

$10 ⟷ **$10K**

Statewide incentive programs for COVID-19 included lottery and guaranteed incentives with the following values:

- **Lottery Prizes:** OH, CO, NY, NM, WA, NC, MA, DE, MI, ME, IL, LA, NV, MO, AR, and CA offered cash incentives ranging from **$302,000 to $5 million**, with some states offering **multiple million-dollar** prizes (OH, CO, NC, MA, MI)
- **Gift Cards/Passes:** CT (free drink), NJ (state park pass), MN ($25 ticket/pass), CA ($50 gift card), AR ($20 game/fish certificate), and WV ($100 gift card/US treasury bond)

CONCLUSIONS

The economic burden of vaccine hesitancy includes factors such as **illness-related costs, productivity losses,** and **expenses of interventions and incentives to boost vaccine demand** and is valued in the **billions of dollars** for high income countries, highlighting the importance of targeting underlying causes of hesitancy, such as misinformation.

Through utilizing these data, policymakers will be better equipped to **forecast costs** when planning to roll out vaccination programs or other public health measures to combat vaccine hesitancy.

REFERENCES

1. Abkar R. Ten Threats to Global Health in 2019: World Health Organization 2019. Accessed September 24, 2024. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019

Abbreviations: AR, Arkansas; B, Billion; CA, California; CAD, Canadian Dollar; CO, Colorado; COVID-19, Coronavirus Disease 2019; DE, Delaware; GDP, Gross Domestic Product; ICU, Intensive Care Unit; ICER, Incremental Cost-Effectiveness Ratio; IL, Illinois; K, Thousand; LA, Louisiana; M, Million; MA, Massachusetts; ME, Maine; MI, Michigan; MO, Missouri; NC, North Carolina; NM, New Mexico; NV, Nevada; NY, New York; OECD, Organization for Economic Co-operation and Development; OH, Ohio; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; US, United States; WA, Washington; WTA, Willingness to Accept; WTP, Willingness to Pay